Vanguard Group’s Cumberland Pharmaceuticals CPIX Stock Holding History

Vanguard Group’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.64M	Hold	411,786	–	–	﹤0.01%	3624
2025 Q3	$1.28M	Hold	411,786	–	–	﹤0.01%	3713
2025 Q2	$1.38M	Sell	411,786 -4,783	-1%	-$22.7K	﹤0.01%	3657
2025 Q1	$1.76M	Buy	416,569 +42,318	+11%	+$175K	﹤0.01%	3532
2024 Q4	$887K	Hold	374,251	–	–	﹤0.01%	3803
2024 Q3	$479K	Hold	374,251	–	–	﹤0.01%	3979
2024 Q2	$573K	Hold	374,251	–	–	﹤0.01%	3956
2024 Q1	$629K	Hold	374,251	–	–	﹤0.01%	3959
2023 Q4	$671K	Buy	374,251 +1,125	+0.3%	+$2.06K	﹤0.01%	3949
2023 Q3	$705K	Sell	373,126 -1,700	-0.5%	-$2.85K	﹤0.01%	3952
2023 Q2	$551K	Hold	374,826	–	–	﹤0.01%	4090
2023 Q1	$731K	Hold	374,826	–	–	﹤0.01%	4002
2022 Q4	$843K	Buy	374,826 +135	+0%	+$313	﹤0.01%	3965
2022 Q3	$903K	Hold	374,691	–	–	﹤0.01%	4035
2022 Q2	$778K	Sell	374,691 -3,293	-0.9%	-$7.62K	﹤0.01%	4165
2022 Q1	$1.07M	Sell	377,984 -13,195	-3%	-$43.9K	﹤0.01%	4184
2021 Q4	$1.83M	Sell	391,179 -417	-0.1%	-$1.42K	﹤0.01%	4080
2021 Q3	$1.05M	Hold	391,596	–	–	﹤0.01%	4234
2021 Q2	$1.11M	Hold	391,596	–	–	﹤0.01%	4127
2021 Q1	$1.19M	Hold	391,596	–	–	﹤0.01%	3978
2020 Q4	$1.16M	Sell	391,596 -99	-0%	-$300	﹤0.01%	3791
2020 Q3	$1.26M	Hold	391,695	–	–	﹤0.01%	3604
2020 Q2	$1.3M	Hold	391,695	–	–	﹤0.01%	3544
2020 Q1	$1.42M	Hold	391,695	–	–	﹤0.01%	3395
2019 Q4	$2.02M	Buy	391,695 +99	+0%	+$523	﹤0.01%	3448
2019 Q3	$2.32M	Buy	391,596 +22,871	+6%	+$127K	﹤0.01%	3402
2019 Q2	$2.35M	Hold	368,725	–	–	﹤0.01%	3427
2019 Q1	$2.14M	Buy	368,725 +54,701	+17%	+$317K	﹤0.01%	3427
2018 Q4	$1.98M	Buy	314,024 +260	+0.1%	+$1.56K	﹤0.01%	3378
2018 Q3	$1.79M	Hold	313,764	–	–	﹤0.01%	3565
2018 Q2	$1.92M	Hold	313,764	–	–	﹤0.01%	3508
2018 Q1	$2.1M	Sell	313,764 -2,473	-0.8%	-$17K	﹤0.01%	3448
2017 Q4	$2.35M	Buy	316,237 +13,287	+4%	+$97.8K	﹤0.01%	3375
2017 Q3	$2.14M	Buy	302,950 +4,315	+1%	+$29.8K	﹤0.01%	3377
2017 Q2	$2.11M	Buy	298,635 +1,180	+0.4%	+$7.78K	﹤0.01%	3365
2017 Q1	$2.06M	Hold	297,455	–	–	﹤0.01%	3370
2016 Q4	$1.64M	Sell	297,455 -668	-0.2%	-$3.48K	﹤0.01%	3424
2016 Q3	$1.49M	Buy	298,123 +900	+0.3%	+$4.23K	﹤0.01%	3472
2016 Q2	$1.34M	Buy	297,223 +2,600	+0.9%	+$11.9K	﹤0.01%	3521
2016 Q1	$1.32M	Buy	294,623 +5,003	+2%	+$23.8K	﹤0.01%	3513
2015 Q4	$1.52M	Buy	289,620 +5,500	+2%	+$31.3K	﹤0.01%	3494
2015 Q3	$1.64M	Hold	284,120	–	–	﹤0.01%	3460
2015 Q2	$2.03M	Sell	284,120 -1,426	-0.5%	-$9.91K	﹤0.01%	3414
2015 Q1	$1.9M	Buy	285,546 +6,114	+2%	+$38.2K	﹤0.01%	3436
2014 Q4	$1.68M	Buy	279,432 +7,700	+3%	+$39.5K	﹤0.01%	3345
2014 Q3	$1.34M	Hold	271,732	–	–	﹤0.01%	3417
2014 Q2	$1.22M	Buy	271,732 +2,900	+1%	+$12.9K	﹤0.01%	3438
2014 Q1	$1.21M	Buy	268,832 +1,000	+0.4%	+$4.76K	﹤0.01%	3396
2013 Q4	$1.37M	Hold	267,832	–	–	﹤0.01%	3326
2013 Q3	$1.21M	Hold	267,832	–	–	﹤0.01%	3315
2013 Q2	$1.37M	Buy	+267,832	New	+$1.33M	﹤0.01%	3204

Other funds holding CPIX

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's CPIX Position: Q4 2025 in Review

Vanguard Group held its Cumberland Pharmaceuticals (CPIX) position steady in Q4 2025 at 411,786 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3624.

Vanguard Group first reported a position in CPIX in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.35M in Q2 2019. 27 funds tracked by Wall St. Rank hold CPIX as of Q4 2025.

Vanguard Group held 411,786 shares of Cumberland Pharmaceuticals worth $1.64M as of Q4 2025.
Vanguard Group left its Cumberland Pharmaceuticals share count unchanged in Q4 2025.
Cumberland Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3624 holding.
Vanguard Group first reported a position in Cumberland Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Vanguard Group's Cumberland Pharmaceuticals position peaked at $2.35M in Q2 2019.
27 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.